A Prospective Randomised Comparison of CMF versus Sequential Epirubicin Followed by CMF as Adjuvant Chemotherapy for Women with Early Breast Cancer
Completed
- Conditions
- BreastCancerBreast cancer
- Registration Number
- ISRCTN35478997
- Lead Sponsor
- Pharmacia Ltd & Upjohn (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 0
Inclusion Criteria
1. Histologically confirmed breast cancer
2. Histologically confirmed axillary node metastases
3. Fit to receive chemotherapy on either arm of the trial
4. Adequate hepatic, renal and bone marrow function
5. No previous chemotherapy
6. No prior or concomitant malignancy, except basal cell carcinoma or in situ carcinoma of the cervix
7. No bilateral breast tumours or locally advanced or metastatic breast cancer, including supraclavicular fossa metastases
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration